493 related articles for article (PubMed ID: 16172461)
61. Different mutation profiles associated to P53 accumulation in colorectal cancer.
López I; P Oliveira L; Tucci P; Alvarez-Valín F; A Coudry R; Marín M
Gene; 2012 May; 499(1):81-7. PubMed ID: 22373952
[TBL] [Abstract][Full Text] [Related]
62. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
[TBL] [Abstract][Full Text] [Related]
63. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
Geisler S; Børresen-Dale AL; Johnsen H; Aas T; Geisler J; Akslen LA; Anker G; Lønning PE
Clin Cancer Res; 2003 Nov; 9(15):5582-8. PubMed ID: 14654539
[TBL] [Abstract][Full Text] [Related]
64. Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival.
Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
Anticancer Res; 2006; 26(2B):1425-32. PubMed ID: 16619554
[TBL] [Abstract][Full Text] [Related]
65. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Havrilesky L; Darcy kM; Hamdan H; Priore RL; Leon J; Bell J; Berchuck A;
J Clin Oncol; 2003 Oct; 21(20):3814-25. PubMed ID: 14551300
[TBL] [Abstract][Full Text] [Related]
66. Is there a role for routine p53 testing in colorectal cancer?
Hoff PM
J Clin Oncol; 2005 Oct; 23(30):7395-6. PubMed ID: 16186590
[No Abstract] [Full Text] [Related]
67. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
[TBL] [Abstract][Full Text] [Related]
68. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon.
Pricolo VE; Finkelstein SD; Wu TT; Keller G; Bakker A; Swalsky PA; Bland KI
Am J Surg; 1996 Jan; 171(1):41-6. PubMed ID: 8554149
[TBL] [Abstract][Full Text] [Related]
69. p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy.
Buglioni S; D'Agnano I; Vasselli S; Perrone Donnorso R; D'Angelo C; Brenna A; Benevolo M; Cosimelli M; Zupi G; Mottolese M
Am J Clin Pathol; 2001 Sep; 116(3):360-8. PubMed ID: 11554164
[TBL] [Abstract][Full Text] [Related]
70. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location.
Gervaz P; Bouzourene H; Cerottini JP; Chaubert P; Benhattar J; Secic M; Wexner S; Givel JC; Belin B
Dis Colon Rectum; 2001 Mar; 44(3):364-72; discussion 372-3. PubMed ID: 11289282
[TBL] [Abstract][Full Text] [Related]
71. [Prognostic value of the presence of the mutation of the codons 12, 13 and 61 in K-ras oncogene in colorectal cancer].
Pajkos G; Kiss I; Sándor J; Ember I; Kisházi P
Orv Hetil; 1999 Jul; 140(30):1673-9. PubMed ID: 10461447
[TBL] [Abstract][Full Text] [Related]
72. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
[TBL] [Abstract][Full Text] [Related]
73. Altered subcellular localization of suppressin, a novel inhibitor of cell-cycle entry, is an independent prognostic factor in colorectal adenocarcinomas.
Manne U; Gary BD; Oelschlager DK; Weiss HL; Frost AR; Grizzle WE
Clin Cancer Res; 2001 Nov; 7(11):3495-503. PubMed ID: 11705868
[TBL] [Abstract][Full Text] [Related]
74. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
Jensen SA; Vainer B; Witton CJ; Jørgensen JT; Sørensen JB
Acta Oncol; 2008; 47(6):1054-61. PubMed ID: 18607850
[TBL] [Abstract][Full Text] [Related]
75. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis.
Pakos EE; Kyzas PA; Ioannidis JP
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6208-14. PubMed ID: 15448009
[TBL] [Abstract][Full Text] [Related]
76. TP53 gene mutations in prostate cancer progression.
Ecke TH; Schlechte HH; Schiemenz K; Sachs MD; Lenk SV; Rudolph BD; Loening SA
Anticancer Res; 2010 May; 30(5):1579-86. PubMed ID: 20592345
[TBL] [Abstract][Full Text] [Related]
77. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y
BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513
[TBL] [Abstract][Full Text] [Related]
78. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
Etienne-Grimaldi MC; Formento JL; Francoual M; François E; Formento P; Renée N; Laurent-Puig P; Chazal M; Benchimol D; Delpero JR; Letoublon C; Pezet D; Seitz JF; Milano G
Clin Cancer Res; 2008 Aug; 14(15):4830-5. PubMed ID: 18676755
[TBL] [Abstract][Full Text] [Related]
79. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K
Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585
[TBL] [Abstract][Full Text] [Related]
80. Evaluation of genetic mutations of tumor suppresser genes in colorectal cancer patients.
Kubo H; Miki C; Kusunoki M
Hepatogastroenterology; 2004; 51(55):114-7. PubMed ID: 15011843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
